JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$3.46B |
| 2 |
Microsoft
MSFT
|
+$2.83B |
| 3 |
Eli Lilly
LLY
|
+$2.1B |
| 4 |
Broadcom
AVGO
|
+$1.33B |
| 5 |
Stryker
SYK
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$3.18B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$2.39B |
| 3 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$2.35B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$2.07B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.04% |
| 2 | Technology | 20.48% |
| 3 | Healthcare | 9.65% |
| 4 | Financials | 9.27% |
| 5 | Consumer Discretionary | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4101
Amylyx Pharmaceuticals
AMLX
$3.55B
| $1.06M | ﹤0.01% |
71,888
-19,077
| -21% | -$292K |
2022 Q1
7 quarters
|
|
|
PEGR
4102
DELISTED
Project Energy Reimagined Acquisition Corp. Class A Ordinary Share
PEGR
| $1.06M | ﹤0.01% |
99,997
-80,003
| -44% | -$841K |
2023 Q3
1 quarter
|
|
4103
Accel Entertainment
ACEL
$880M
| $1.06M | ﹤0.01% |
102,789
+63,169
| +159% | +$651K |
2020 Q2
14 quarters
|
|
4104
Planet Labs
PL
$6.37B
| $1.05M | ﹤0.01% |
426,783
+135,605
| +47% | +$321K |
2021 Q4
8 quarters
|
|
4105
CALL
SharkNinja
SN
$25.7B
| $1.05M | ﹤0.01% |
+20,600
| New | +$942K |
2023 Q4
0 quarters
|
|
|
CATC
4106
DELISTED
CAMBRIDGE BANCORP
CATC
| $1.05M | ﹤0.01% |
15,103
+9,902
| +190% | +$605K |
2018 Q2
22 quarters
|
|
4107
Bristow Group
VTOL
$1.19B
| $1.05M | ﹤0.01% |
37,070
+9,017
| +32% | +$244K |
2015 Q4
32 quarters
|
|
4108
Ternium
TX
$11.1B
| $1.05M | ﹤0.01% |
24,656
-70
| -0.3% | -$2.71K |
2015 Q4
32 quarters
|
|
4109
TORM
TRMD
$4.11B
| $1.05M | ﹤0.01% |
+34,427
| New | +$1.02M |
2023 Q4
0 quarters
|
|
4110
CALL
The Mosaic Company
MOS
$6.7B
| $1.05M | ﹤0.01% |
+29,300
| New | +$1.03M |
2023 Q4
0 quarters
|
|
|
SVM
4111
Silvercorp Metals
SVM
$2.34B
| $1.04M | ﹤0.01% |
396,919
-94,131
| -19% | -$231K |
2017 Q2
26 quarters
|
|
4112
CALL
Cytokinetics
CYTK
$9.12B
| $1.04M | ﹤0.01% |
+12,500
| New | +$453K |
2023 Q4
0 quarters
|
|
4113
Takeda Pharmaceutical
TAK
$57.1B
| $1.04M | ﹤0.01% |
73,080
-219,052
| -75% | -$3.11M |
2018 Q4
20 quarters
|
|
4114
Allient
ALNT
$2.01B
| $1.04M | ﹤0.01% |
34,498
-94,667
| -73% | -$2.67M |
2017 Q4
24 quarters
|
|
4115
Neumora Therapeutics
NMRA
$93.9M
| $1.04M | ﹤0.01% |
+61,117
| New | +$750K |
2023 Q4
0 quarters
|
|
4116
CALL
Ross Stores
ROST
$73B
| $1.04M | ﹤0.01% |
7,500
-39,800
| -84% | -$4.96M |
2023 Q3
1 quarter
|
|
|
SPLK
4117
CALL
DELISTED
Splunk Inc
SPLK
| $1.04M | ﹤0.01% |
6,800
-2,600
| -28% | -$388K |
2022 Q1
7 quarters
|
|
4118
CALL
Ollie's Bargain Outlet
OLLI
$5.23B
| $1.03M | ﹤0.01% |
+13,600
| New | +$1.02M |
2023 Q4
0 quarters
|
|
4119
VanEck Morningstar International Moat ETF
MOTI
$68.8M
| $1.03M | ﹤0.01% |
33,078
+5,174
| +19% | +$155K |
2023 Q1
3 quarters
|
|
4120
PUT
Sherwin-Williams
SHW
$77.6B
| $1.03M | ﹤0.01% |
3,300
| – | – |
2022 Q4
4 quarters
|
|
4121
PIMCO RAFI Multi-Factor International Equity ETF
MFDX
$455M
| $1.02M | ﹤0.01% |
35,055
-17,510
| -33% | -$479K |
2023 Q2
2 quarters
|
|
4122
Karyopharm Therapeutics
KPTI
$18.2M
| $1.02M | ﹤0.01% |
78,741
+2,666
| +4% | +$35.9K |
2013 Q4
40 quarters
|
|
4123
Altimmune
ALT
$531M
| $1.02M | ﹤0.01% |
90,795
+30,467
| +51% | +$127K |
2020 Q4
12 quarters
|
|
4124
Cartesian Therapeutics
RNAC
$223M
| $1.02M | ﹤0.01% |
49,360
-674
| -1% | -$20.1K |
2020 Q2
14 quarters
|
|
|
INVX
4125
Innovex International
INVX
$1.91B
| $1.02M | ﹤0.01% |
43,861
-15,131
| -26% | -$355K |
2013 Q2
42 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2023 Portfolio in Review
As of Q4 2023, JP Morgan Chase held 8,129 positions worth $1.04T, up 15% from $906B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
JP Morgan Chase's Q4 2023 filing shows 701 new, 3,661 increased, 2,247 reduced and 617 closed positions. Its largest new stake was JPMorgan US Tech Leaders ETF: 3,149,069 shares worth $185M. The largest sale was Vanguard S&P 500 ETF, an estimated $3.18B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q4 2023 buy was JPMorgan US Tech Leaders ETF: 3,149,069 shares worth $185M.
- JP Morgan Chase added most to Vanguard Intermediate-Term Corporate Bond ETF in Q4 2023, an estimated $3.46B increase.
- JP Morgan Chase's biggest Q4 2023 reduction was Vanguard S&P 500 ETF, cutting an estimated $3.18B.
- JP Morgan Chase fully exited Activision Blizzard in Q4 2023, selling an estimated $1.06B.
- JP Morgan Chase's ten largest holdings make up 20% of its $1.04T portfolio in Q4 2023.
- JP Morgan Chase opened 701 new positions and closed 617 in Q4 2023.
- JP Morgan Chase's portfolio value rose 15% quarter-over-quarter to $1.04T.
Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.